Ultragenyx Pharmaceutical Inc.
Price Action
Technical Summary
CONSOLIDATINGUltragenyx Pharmaceutical Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 79), indicating performance broadly in line with the market. Earnings contraction of 17% provides fundamental context to the price action. However, with RSI at 76, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $28.33 | +26.60% | ABOVE |
| 50 SMA | $25.89 | +38.55% | ABOVE |
| 100 SMA | $24.06 | +49.10% | ABOVE |
| 150 SMA | $25.43 | +41.05% | ABOVE |
| 200 SMA | $27.07 | +32.49% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RARE in an uptrend right now?
RARE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is RARE overbought or oversold?
RARE's RSI (14) is 76. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is RARE outperforming the market?
RARE has a Relative Strength (RS) Rating of 79 out of 99. RARE is performing about average compared to the market.
Where is RARE in its 52-week range?
RARE is trading at $35.87, which is 85% of its 52-week high ($42.37) and 73% above its 52-week low ($18.29).
How volatile is RARE?
RARE has a Beta of 1.33 and 52-week volatility of 72%. It's more volatile than the S&P 500 - expect bigger swings.